Moderna president: ‘We don't really know' if future COVID-19 shots will be necessary_老虎社区_美港股上老虎

Moderna president: ‘We don't really know' if future COVID-19 shots will be necessary

finance.yahoo2021-09-17

Amid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown. "We...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

41e183
·2021-09-17
Ooo
回复
2
举报
收起
- Andr3:
  comment
  2021-09-17
  回复
  举报
6f284a23
·2021-09-17
Like
回复
5
举报
收起
- 41e183:
  Like
  2021-09-17
  回复
  举报
31ef55f0
·2021-09-17
Like pls
回复
6
举报
收起
- DragonKing回复43c0b98:
  yeah
  2021-09-17
  回复
  举报
- fann:
  h
  2021-09-17
  回复
  举报
- JiaLe:
  Ok
  2021-09-17
  回复
  举报
查看更多 2 条评论
Catherinee
·2021-09-17
Yes
回复
6
举报
收起
- themonkey:
  yes
  2021-09-17
  回复
  举报
- 31ef55f0:
  Yes
  2021-09-17
  回复
  举报
- 43c0b98:
  Time to piak piak already la
  2021-09-17
  回复
  举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1120326613?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-09-17 13:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120326613","market":"us","top_or_hot":-1,"title":"Moderna president: ‘We don't really know' if future COVID-19 shots will be necessary","media":"finance.yahoo","content":"<div>\nAmid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.\n\"We...\n\n<a href=\"https://finance.yahoo.com/news/moderna-we-dont-really-know-if-a-third-covid-19-shot-is-necessary-135143605.html\">网页链接</a>\n\n</div>\n","source":"lsy1612507957220","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna president: ‘We don't really know' if future COVID-19 shots will be necessary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna president: ‘We don't really know' if future COVID-19 shots will be necessary\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-17 13:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-we-dont-really-know-if-a-third-covid-19-shot-is-necessary-135143605.html>finance.yahoo</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nAmid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.\n\"We...\n\n<a href=\"https://finance.yahoo.com/news/moderna-we-dont-really-know-if-a-third-covid-19-shot-is-necessary-135143605.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/moderna-we-dont-really-know-if-a-third-covid-19-shot-is-necessary-135143605.html","article_id":"1120326613","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120326613","pubTimestamp":1631857028,"columns":[],"sourceInfo":{"source_id":"lsy1612507957220","name":"finance.yahoo"},"weMediaInfo":null,"summary":"Amid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"莫德纳主席：“我们真的不知道”未来的新冠肺炎镜头是否有必要","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Amid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.\n\"We don't really know\" if a third shot will be the final or if more are needed, Hoge told Yahoo Finance.\nIn addition, who would benefit most from an additional shot is still a question.\n\"This is the key scientific question we're all wrestling with now,\" Hoge said.\nIf an additional dose does prove to provide some level of increased protection, it would likely be necessary when late fall and winter approach, when respiratory illnesses thrive and breakthrough cases are likely to increase, he noted.\nHealth experts have been watching the upcoming seasons with dread, anticipating yet another surge in cases nationwide. The severity of those cases could be low considering the higher levels of vaccination, but the Delta variant is proving to be capable of increasing breakthrough cases and other variants could develop and spread by the year's end.\nIt's why some experts have said that the current level of vaccination is sufficient and the memory cells, whose job it is to remember how to fight off COVID-19 after being trained by the vaccine, should be relied on.\nOthers however are relying on antibody levels, which are typically highest after a vaccine, in order to determine when to boost.\nBut Hoge said he disagrees the two are mutually exclusive. \"We think ... the debate between whether it's memory cells or antibody titers is a bit false. Both are important,\" he said.\nIn data released Wednesday, Moderna showed better protection against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the elderly and immunocompromised — the latter of which has already received authorization for boosters by the FDA.\nModerna is also seeking authorization for its booster dose, which is 50 micrograms, half the dose of the original shot. It anticipates getting FDA authorization not long after Pfizer (PFE), whose advisory panel hearing is set for September 17.\nManufacturing boost for Moderna\nIn addition, Moderna is eyeing the potential to increase manufacturing as a result of a lower booster dose. That's an area where, unlike the other vaccine companies, Moderna still lags.\nThe once-small biotech has seen a boost in the company's stock since arriving on the COVID-19 vaccine scene last year. The surge in available capital is allowing it to increase its manufacturing amid the pandemic but at a slower pace.\n\"For us as a company, we are flat out in manufacturing,\" Hoge said.\nThe company has relied on third parties, known as contract manufacturers, which hasn't been without problems, which is why the company has to focus on expansion while still making good on existing dose commitments.\n\"We are making as much as we can, and have been for the better part of a year — and will be for the better part of the next year. We are trying to scale up and invest in manufacturing to create more doses,\" Hoge said.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":884326592,"gmtCreate":1631859319416,"gmtModify":1631890142059,"author":{"id":"4088412711170620","authorId":"4088412711170620","name":"41e183","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"4088412711170620","authorIdStr":"4088412711170620"},"htmlText":"Ooo","listText":"Ooo","text":"Ooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/884326592","repostId":1120326613,"repostType":4,"repost":{"id":"1120326613","kind":"news","pubTimestamp":1631857028,"share":"https://www.laohu8.com/m/news/1120326613?lang=zh_CN&edition=full","pubTime":"2021-09-17 13:37","market":"us","language":"en","title":"Moderna president: ‘We don't really know' if future COVID-19 shots will be necessary<blockquote>Moderna总裁：“我们真的不知道”未来是否有必要注射COVID-19疫苗</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1120326613","media":"finance.yahoo","summary":"Amid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses","content":"Amid the&nbsp;growing controversy&nbsp;over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.<blockquote>Moderna(MRNA)总裁斯蒂芬·霍格(Stephen Hoge)承认，关于美国是否需要加强疫苗或额外疫苗剂量来预防COVID-19的争议越来越大。</blockquote> \"We don't really know\" if a third shot will be the final or if more are needed, Hoge told Yahoo Finance.<blockquote>霍格告诉雅虎财经，“我们真的不知道”第三次注射是否会是最后一次，或者是否需要更多。</blockquote> In addition, who would benefit most from an additional shot is still a question.<blockquote>此外，谁将从额外的注射中受益最大仍然是一个问题。</blockquote> \"This is the key scientific question we're all wrestling with now,\" Hoge said.<blockquote>“这是我们现在都在努力解决的关键科学问题，”霍格说。</blockquote> If an additional dose does prove to provide some level of increased protection, it would likely be necessary when late fall and winter approach, when respiratory illnesses thrive and breakthrough cases are likely to increase, he noted.<blockquote>他指出，如果额外剂量确实被证明可以提供某种程度的增强保护，那么当深秋和冬季临近时，呼吸道疾病猖獗，突破性病例可能会增加，这可能是必要的。</blockquote> Health experts have been watching the upcoming seasons with dread, anticipating yet another surge in cases nationwide. The severity of those cases could be low considering the higher levels of vaccination, but the Delta variant is proving to be capable of increasing breakthrough cases and other variants could develop and spread by the year's end.<blockquote>健康专家一直在恐惧地关注着即将到来的季节，预计全国范围内的病例将再次激增。考虑到疫苗接种水平较高，这些病例的严重程度可能较低，但事实证明，德尔塔变异毒株有能力增加突破性病例，其他变种可能会在年底前发展和传播。</blockquote> It's why some experts have said that the current level of vaccination is sufficient and the memory cells, whose job it is to remember how to fight off COVID-19 after being trained by the vaccine, should be relied on.<blockquote>这就是为什么一些专家说，目前的疫苗接种水平是足够的，应该依靠记忆细胞，记忆细胞的工作是在接受疫苗训练后记住如何击退新冠肺炎。</blockquote> Others however are relying on antibody levels, which are typically highest after a vaccine, in order to determine when to boost.<blockquote>然而，其他人依靠抗体水平（通常在接种疫苗后最高）来确定何时加强免疫。</blockquote> But Hoge said he disagrees the two are mutually exclusive. \"We think ... the debate between whether it's memory cells or antibody titers is a bit false. Both are important,\" he said.<blockquote>但是霍格说他不同意这两者是相互排斥的。“我们认为……关于记忆细胞还是抗体滴度的争论有点错误。两者都很重要，”他说。</blockquote> In data released Wednesday,&nbsp;Moderna showed better protection&nbsp;against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the elderly and immunocompromised — the latter of which has already received authorization for boosters by the FDA.<blockquote>在周三发布的数据中，与一年后相比，Moderna在首次注射8个月后对突破性病例表现出更好的保护作用。但最大的好处将来自老年人和免疫功能低下者——后者已经获得了FDA的加强剂授权。</blockquote> Moderna is also seeking authorization for its booster dose, which is 50 micrograms, half the dose of the original shot. It anticipates getting FDA authorization not long after Pfizer (PFE), whose advisory panel hearing is set for September 17.<blockquote>Moderna还在寻求其加强剂量的授权，该剂量为50微克，是原始注射剂量的一半。预计辉瑞(PFE)将在辉瑞(PFE)的顾问小组听证会定于9月17日举行后不久获得FDA授权。</blockquote> Manufacturing boost for Moderna<blockquote>Moderna的制造业增长</blockquote> In addition, Moderna is eyeing the potential to&nbsp;increase manufacturing&nbsp;as a result of a lower booster dose. That's an area where, unlike the other vaccine companies, Moderna still lags.<blockquote>此外，Moderna正在关注由于较低的加强剂量而增加产量的潜力。与其他疫苗公司不同，Moderna在这一领域仍然落后。</blockquote> The once-small biotech has seen a boost in the company's stock since arriving on the COVID-19 vaccine scene last year. The surge in available capital is allowing it to increase its manufacturing amid the pandemic but at a slower pace.<blockquote>自去年进入COVID-19疫苗领域以来，这家曾经规模较小的生物技术公司的股价有所上涨。可用资本的激增使其能够在疫情期间增加制造业，但速度较慢。</blockquote> \"For us as a company, we are flat out in manufacturing,\" Hoge said.<blockquote>“对于我们作为一家公司来说，我们在制造业方面全力以赴，”霍格说。</blockquote> The company has relied on third parties, known as contract manufacturers, which&nbsp;hasn't been without problems, which is why the company has to focus on expansion while still making good on existing dose commitments.<blockquote>该公司一直依赖第三方，即合同制造商，这并非没有问题，这就是为什么该公司必须专注于扩张，同时仍然兑现现有的剂量承诺。</blockquote> \"We are making as much as we can, and have been for the better part of a year — and will be for the better part of the next year. We are trying to scale up and invest in manufacturing to create more doses,\" Hoge said.<blockquote>霍格说：“我们正在尽可能多地生产，今年的大部分时间都是如此，明年的大部分时间也将如此。我们正在努力扩大规模并投资于制造，以生产更多剂量。”</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna president: ‘We don't really know' if future COVID-19 shots will be necessary<blockquote>Moderna总裁：“我们真的不知道”未来是否有必要注射COVID-19疫苗</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna president: ‘We don't really know' if future COVID-19 shots will be necessary<blockquote>Moderna总裁：“我们真的不知道”未来是否有必要注射COVID-19疫苗</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nfinance.yahoo2021-09-17 13:37\n\n</h4>\n</header>\n<article>\nAmid the&nbsp;growing controversy&nbsp;over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.<blockquote>Moderna(MRNA)总裁斯蒂芬·霍格(Stephen Hoge)承认，关于美国是否需要加强疫苗或额外疫苗剂量来预防COVID-19的争议越来越大。</blockquote> \"We don't really know\" if a third shot will be the final or if more are needed, Hoge told Yahoo Finance.<blockquote>霍格告诉雅虎财经，“我们真的不知道”第三次注射是否会是最后一次，或者是否需要更多。</blockquote> In addition, who would benefit most from an additional shot is still a question.<blockquote>此外，谁将从额外的注射中受益最大仍然是一个问题。</blockquote> \"This is the key scientific question we're all wrestling with now,\" Hoge said.<blockquote>“这是我们现在都在努力解决的关键科学问题，”霍格说。</blockquote> If an additional dose does prove to provide some level of increased protection, it would likely be necessary when late fall and winter approach, when respiratory illnesses thrive and breakthrough cases are likely to increase, he noted.<blockquote>他指出，如果额外剂量确实被证明可以提供某种程度的增强保护，那么当深秋和冬季临近时，呼吸道疾病猖獗，突破性病例可能会增加，这可能是必要的。</blockquote> Health experts have been watching the upcoming seasons with dread, anticipating yet another surge in cases nationwide. The severity of those cases could be low considering the higher levels of vaccination, but the Delta variant is proving to be capable of increasing breakthrough cases and other variants could develop and spread by the year's end.<blockquote>健康专家一直在恐惧地关注着即将到来的季节，预计全国范围内的病例将再次激增。考虑到疫苗接种水平较高，这些病例的严重程度可能较低，但事实证明，德尔塔变异毒株有能力增加突破性病例，其他变种可能会在年底前发展和传播。</blockquote> It's why some experts have said that the current level of vaccination is sufficient and the memory cells, whose job it is to remember how to fight off COVID-19 after being trained by the vaccine, should be relied on.<blockquote>这就是为什么一些专家说，目前的疫苗接种水平是足够的，应该依靠记忆细胞，记忆细胞的工作是在接受疫苗训练后记住如何击退新冠肺炎。</blockquote> Others however are relying on antibody levels, which are typically highest after a vaccine, in order to determine when to boost.<blockquote>然而，其他人依靠抗体水平（通常在接种疫苗后最高）来确定何时加强免疫。</blockquote> But Hoge said he disagrees the two are mutually exclusive. \"We think ... the debate between whether it's memory cells or antibody titers is a bit false. Both are important,\" he said.<blockquote>但是霍格说他不同意这两者是相互排斥的。“我们认为……关于记忆细胞还是抗体滴度的争论有点错误。两者都很重要，”他说。</blockquote> In data released Wednesday,&nbsp;Moderna showed better protection&nbsp;against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the elderly and immunocompromised — the latter of which has already received authorization for boosters by the FDA.<blockquote>在周三发布的数据中，与一年后相比，Moderna在首次注射8个月后对突破性病例表现出更好的保护作用。但最大的好处将来自老年人和免疫功能低下者——后者已经获得了FDA的加强剂授权。</blockquote> Moderna is also seeking authorization for its booster dose, which is 50 micrograms, half the dose of the original shot. It anticipates getting FDA authorization not long after Pfizer (PFE), whose advisory panel hearing is set for September 17.<blockquote>Moderna还在寻求其加强剂量的授权，该剂量为50微克，是原始注射剂量的一半。预计辉瑞(PFE)将在辉瑞(PFE)的顾问小组听证会定于9月17日举行后不久获得FDA授权。</blockquote> Manufacturing boost for Moderna<blockquote>Moderna的制造业增长</blockquote> In addition, Moderna is eyeing the potential to&nbsp;increase manufacturing&nbsp;as a result of a lower booster dose. That's an area where, unlike the other vaccine companies, Moderna still lags.<blockquote>此外，Moderna正在关注由于较低的加强剂量而增加产量的潜力。与其他疫苗公司不同，Moderna在这一领域仍然落后。</blockquote> The once-small biotech has seen a boost in the company's stock since arriving on the COVID-19 vaccine scene last year. The surge in available capital is allowing it to increase its manufacturing amid the pandemic but at a slower pace.<blockquote>自去年进入COVID-19疫苗领域以来，这家曾经规模较小的生物技术公司的股价有所上涨。可用资本的激增使其能够在疫情期间增加制造业，但速度较慢。</blockquote> \"For us as a company, we are flat out in manufacturing,\" Hoge said.<blockquote>“对于我们作为一家公司来说，我们在制造业方面全力以赴，”霍格说。</blockquote> The company has relied on third parties, known as contract manufacturers, which&nbsp;hasn't been without problems, which is why the company has to focus on expansion while still making good on existing dose commitments.<blockquote>该公司一直依赖第三方，即合同制造商，这并非没有问题，这就是为什么该公司必须专注于扩张，同时仍然兑现现有的剂量承诺。</blockquote> \"We are making as much as we can, and have been for the better part of a year — and will be for the better part of the next year. We are trying to scale up and invest in manufacturing to create more doses,\" Hoge said.<blockquote>霍格说：“我们正在尽可能多地生产，今年的大部分时间都是如此，明年的大部分时间也将如此。我们正在努力扩大规模并投资于制造，以生产更多剂量。”</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-we-dont-really-know-if-a-third-covid-19-shot-is-necessary-135143605.html\">finance.yahoo</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-we-dont-really-know-if-a-third-covid-19-shot-is-necessary-135143605.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120326613","content_text":"Amid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.\n\"We don't really know\" if a third shot will be the final or if more are needed, Hoge told Yahoo Finance.\nIn addition, who would benefit most from an additional shot is still a question.\n\"This is the key scientific question we're all wrestling with now,\" Hoge said.\nIf an additional dose does prove to provide some level of increased protection, it would likely be necessary when late fall and winter approach, when respiratory illnesses thrive and breakthrough cases are likely to increase, he noted.\nHealth experts have been watching the upcoming seasons with dread, anticipating yet another surge in cases nationwide. The severity of those cases could be low considering the higher levels of vaccination, but the Delta variant is proving to be capable of increasing breakthrough cases and other variants could develop and spread by the year's end.\nIt's why some experts have said that the current level of vaccination is sufficient and the memory cells, whose job it is to remember how to fight off COVID-19 after being trained by the vaccine, should be relied on.\nOthers however are relying on antibody levels, which are typically highest after a vaccine, in order to determine when to boost.\nBut Hoge said he disagrees the two are mutually exclusive. \"We think ... the debate between whether it's memory cells or antibody titers is a bit false. Both are important,\" he said.\nIn data released Wednesday, Moderna showed better protection against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the elderly and immunocompromised — the latter of which has already received authorization for boosters by the FDA.\nModerna is also seeking authorization for its booster dose, which is 50 micrograms, half the dose of the original shot. It anticipates getting FDA authorization not long after Pfizer (PFE), whose advisory panel hearing is set for September 17.\nManufacturing boost for Moderna\nIn addition, Moderna is eyeing the potential to increase manufacturing as a result of a lower booster dose. That's an area where, unlike the other vaccine companies, Moderna still lags.\nThe once-small biotech has seen a boost in the company's stock since arriving on the COVID-19 vaccine scene last year. The surge in available capital is allowing it to increase its manufacturing amid the pandemic but at a slower pace.\n\"For us as a company, we are flat out in manufacturing,\" Hoge said.\nThe company has relied on third parties, known as contract manufacturers, which hasn't been without problems, which is why the company has to focus on expansion while still making good on existing dose commitments.\n\"We are making as much as we can, and have been for the better part of a year — and will be for the better part of the next year. We are trying to scale up and invest in manufacturing to create more doses,\" Hoge said.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5900406,"gmtCreate":1631859327902,"gmtModify":1631890142061,"authorId":3570549774646276,"author":{"id":3570549774646276,"idStr":"3570549774646276","authorId":3570549774646276,"name":"Andr3","avatar":"https://static.tigerbbs.com/c41ca7aea5e2b5f410896f8cdc5a940c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884326592,"type":1,"supId":0,"prevId":0,"content":"comment","text":"comment","html":"comment"}],"langContent":"EN"},{"id":884329916,"gmtCreate":1631858687135,"gmtModify":1631888961691,"author":{"id":"3586820830754122","authorId":"3586820830754122","name":"6f284a23","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3586820830754122","authorIdStr":"3586820830754122"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/884329916","repostId":1120326613,"repostType":4,"repost":{"id":"1120326613","kind":"news","pubTimestamp":1631857028,"share":"https://www.laohu8.com/m/news/1120326613?lang=zh_CN&edition=full","pubTime":"2021-09-17 13:37","market":"us","language":"en","title":"Moderna president: ‘We don't really know' if future COVID-19 shots will be necessary<blockquote>Moderna总裁：“我们真的不知道”未来是否有必要注射COVID-19疫苗</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1120326613","media":"finance.yahoo","summary":"Amid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses","content":"Amid the&nbsp;growing controversy&nbsp;over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.<blockquote>Moderna(MRNA)总裁斯蒂芬·霍格(Stephen Hoge)承认，关于美国是否需要加强疫苗或额外疫苗剂量来预防COVID-19的争议越来越大。</blockquote> \"We don't really know\" if a third shot will be the final or if more are needed, Hoge told Yahoo Finance.<blockquote>霍格告诉雅虎财经，“我们真的不知道”第三次注射是否会是最后一次，或者是否需要更多。</blockquote> In addition, who would benefit most from an additional shot is still a question.<blockquote>此外，谁将从额外的注射中受益最大仍然是一个问题。</blockquote> \"This is the key scientific question we're all wrestling with now,\" Hoge said.<blockquote>“这是我们现在都在努力解决的关键科学问题，”霍格说。</blockquote> If an additional dose does prove to provide some level of increased protection, it would likely be necessary when late fall and winter approach, when respiratory illnesses thrive and breakthrough cases are likely to increase, he noted.<blockquote>他指出，如果额外剂量确实被证明可以提供某种程度的增强保护，那么当深秋和冬季临近时，呼吸道疾病猖獗，突破性病例可能会增加，这可能是必要的。</blockquote> Health experts have been watching the upcoming seasons with dread, anticipating yet another surge in cases nationwide. The severity of those cases could be low considering the higher levels of vaccination, but the Delta variant is proving to be capable of increasing breakthrough cases and other variants could develop and spread by the year's end.<blockquote>健康专家一直在恐惧地关注着即将到来的季节，预计全国范围内的病例将再次激增。考虑到疫苗接种水平较高，这些病例的严重程度可能较低，但事实证明，德尔塔变异毒株有能力增加突破性病例，其他变种可能会在年底前发展和传播。</blockquote> It's why some experts have said that the current level of vaccination is sufficient and the memory cells, whose job it is to remember how to fight off COVID-19 after being trained by the vaccine, should be relied on.<blockquote>这就是为什么一些专家说，目前的疫苗接种水平是足够的，应该依靠记忆细胞，记忆细胞的工作是在接受疫苗训练后记住如何击退新冠肺炎。</blockquote> Others however are relying on antibody levels, which are typically highest after a vaccine, in order to determine when to boost.<blockquote>然而，其他人依靠抗体水平（通常在接种疫苗后最高）来确定何时加强免疫。</blockquote> But Hoge said he disagrees the two are mutually exclusive. \"We think ... the debate between whether it's memory cells or antibody titers is a bit false. Both are important,\" he said.<blockquote>但是霍格说他不同意这两者是相互排斥的。“我们认为……关于记忆细胞还是抗体滴度的争论有点错误。两者都很重要，”他说。</blockquote> In data released Wednesday,&nbsp;Moderna showed better protection&nbsp;against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the elderly and immunocompromised — the latter of which has already received authorization for boosters by the FDA.<blockquote>在周三发布的数据中，与一年后相比，Moderna在首次注射8个月后对突破性病例表现出更好的保护作用。但最大的好处将来自老年人和免疫功能低下者——后者已经获得了FDA的加强剂授权。</blockquote> Moderna is also seeking authorization for its booster dose, which is 50 micrograms, half the dose of the original shot. It anticipates getting FDA authorization not long after Pfizer (PFE), whose advisory panel hearing is set for September 17.<blockquote>Moderna还在寻求其加强剂量的授权，该剂量为50微克，是原始注射剂量的一半。预计辉瑞(PFE)将在辉瑞(PFE)的顾问小组听证会定于9月17日举行后不久获得FDA授权。</blockquote> Manufacturing boost for Moderna<blockquote>Moderna的制造业增长</blockquote> In addition, Moderna is eyeing the potential to&nbsp;increase manufacturing&nbsp;as a result of a lower booster dose. That's an area where, unlike the other vaccine companies, Moderna still lags.<blockquote>此外，Moderna正在关注由于较低的加强剂量而增加产量的潜力。与其他疫苗公司不同，Moderna在这一领域仍然落后。</blockquote> The once-small biotech has seen a boost in the company's stock since arriving on the COVID-19 vaccine scene last year. The surge in available capital is allowing it to increase its manufacturing amid the pandemic but at a slower pace.<blockquote>自去年进入COVID-19疫苗领域以来，这家曾经规模较小的生物技术公司的股价有所上涨。可用资本的激增使其能够在疫情期间增加制造业，但速度较慢。</blockquote> \"For us as a company, we are flat out in manufacturing,\" Hoge said.<blockquote>“对于我们作为一家公司来说，我们在制造业方面全力以赴，”霍格说。</blockquote> The company has relied on third parties, known as contract manufacturers, which&nbsp;hasn't been without problems, which is why the company has to focus on expansion while still making good on existing dose commitments.<blockquote>该公司一直依赖第三方，即合同制造商，这并非没有问题，这就是为什么该公司必须专注于扩张，同时仍然兑现现有的剂量承诺。</blockquote> \"We are making as much as we can, and have been for the better part of a year — and will be for the better part of the next year. We are trying to scale up and invest in manufacturing to create more doses,\" Hoge said.<blockquote>霍格说：“我们正在尽可能多地生产，今年的大部分时间都是如此，明年的大部分时间也将如此。我们正在努力扩大规模并投资于制造，以生产更多剂量。”</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna president: ‘We don't really know' if future COVID-19 shots will be necessary<blockquote>Moderna总裁：“我们真的不知道”未来是否有必要注射COVID-19疫苗</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna president: ‘We don't really know' if future COVID-19 shots will be necessary<blockquote>Moderna总裁：“我们真的不知道”未来是否有必要注射COVID-19疫苗</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nfinance.yahoo2021-09-17 13:37\n\n</h4>\n</header>\n<article>\nAmid the&nbsp;growing controversy&nbsp;over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.<blockquote>Moderna(MRNA)总裁斯蒂芬·霍格(Stephen Hoge)承认，关于美国是否需要加强疫苗或额外疫苗剂量来预防COVID-19的争议越来越大。</blockquote> \"We don't really know\" if a third shot will be the final or if more are needed, Hoge told Yahoo Finance.<blockquote>霍格告诉雅虎财经，“我们真的不知道”第三次注射是否会是最后一次，或者是否需要更多。</blockquote> In addition, who would benefit most from an additional shot is still a question.<blockquote>此外，谁将从额外的注射中受益最大仍然是一个问题。</blockquote> \"This is the key scientific question we're all wrestling with now,\" Hoge said.<blockquote>“这是我们现在都在努力解决的关键科学问题，”霍格说。</blockquote> If an additional dose does prove to provide some level of increased protection, it would likely be necessary when late fall and winter approach, when respiratory illnesses thrive and breakthrough cases are likely to increase, he noted.<blockquote>他指出，如果额外剂量确实被证明可以提供某种程度的增强保护，那么当深秋和冬季临近时，呼吸道疾病猖獗，突破性病例可能会增加，这可能是必要的。</blockquote> Health experts have been watching the upcoming seasons with dread, anticipating yet another surge in cases nationwide. The severity of those cases could be low considering the higher levels of vaccination, but the Delta variant is proving to be capable of increasing breakthrough cases and other variants could develop and spread by the year's end.<blockquote>健康专家一直在恐惧地关注着即将到来的季节，预计全国范围内的病例将再次激增。考虑到疫苗接种水平较高，这些病例的严重程度可能较低，但事实证明，德尔塔变异毒株有能力增加突破性病例，其他变种可能会在年底前发展和传播。</blockquote> It's why some experts have said that the current level of vaccination is sufficient and the memory cells, whose job it is to remember how to fight off COVID-19 after being trained by the vaccine, should be relied on.<blockquote>这就是为什么一些专家说，目前的疫苗接种水平是足够的，应该依靠记忆细胞，记忆细胞的工作是在接受疫苗训练后记住如何击退新冠肺炎。</blockquote> Others however are relying on antibody levels, which are typically highest after a vaccine, in order to determine when to boost.<blockquote>然而，其他人依靠抗体水平（通常在接种疫苗后最高）来确定何时加强免疫。</blockquote> But Hoge said he disagrees the two are mutually exclusive. \"We think ... the debate between whether it's memory cells or antibody titers is a bit false. Both are important,\" he said.<blockquote>但是霍格说他不同意这两者是相互排斥的。“我们认为……关于记忆细胞还是抗体滴度的争论有点错误。两者都很重要，”他说。</blockquote> In data released Wednesday,&nbsp;Moderna showed better protection&nbsp;against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the elderly and immunocompromised — the latter of which has already received authorization for boosters by the FDA.<blockquote>在周三发布的数据中，与一年后相比，Moderna在首次注射8个月后对突破性病例表现出更好的保护作用。但最大的好处将来自老年人和免疫功能低下者——后者已经获得了FDA的加强剂授权。</blockquote> Moderna is also seeking authorization for its booster dose, which is 50 micrograms, half the dose of the original shot. It anticipates getting FDA authorization not long after Pfizer (PFE), whose advisory panel hearing is set for September 17.<blockquote>Moderna还在寻求其加强剂量的授权，该剂量为50微克，是原始注射剂量的一半。预计辉瑞(PFE)将在辉瑞(PFE)的顾问小组听证会定于9月17日举行后不久获得FDA授权。</blockquote> Manufacturing boost for Moderna<blockquote>Moderna的制造业增长</blockquote> In addition, Moderna is eyeing the potential to&nbsp;increase manufacturing&nbsp;as a result of a lower booster dose. That's an area where, unlike the other vaccine companies, Moderna still lags.<blockquote>此外，Moderna正在关注由于较低的加强剂量而增加产量的潜力。与其他疫苗公司不同，Moderna在这一领域仍然落后。</blockquote> The once-small biotech has seen a boost in the company's stock since arriving on the COVID-19 vaccine scene last year. The surge in available capital is allowing it to increase its manufacturing amid the pandemic but at a slower pace.<blockquote>自去年进入COVID-19疫苗领域以来，这家曾经规模较小的生物技术公司的股价有所上涨。可用资本的激增使其能够在疫情期间增加制造业，但速度较慢。</blockquote> \"For us as a company, we are flat out in manufacturing,\" Hoge said.<blockquote>“对于我们作为一家公司来说，我们在制造业方面全力以赴，”霍格说。</blockquote> The company has relied on third parties, known as contract manufacturers, which&nbsp;hasn't been without problems, which is why the company has to focus on expansion while still making good on existing dose commitments.<blockquote>该公司一直依赖第三方，即合同制造商，这并非没有问题，这就是为什么该公司必须专注于扩张，同时仍然兑现现有的剂量承诺。</blockquote> \"We are making as much as we can, and have been for the better part of a year — and will be for the better part of the next year. We are trying to scale up and invest in manufacturing to create more doses,\" Hoge said.<blockquote>霍格说：“我们正在尽可能多地生产，今年的大部分时间都是如此，明年的大部分时间也将如此。我们正在努力扩大规模并投资于制造，以生产更多剂量。”</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-we-dont-really-know-if-a-third-covid-19-shot-is-necessary-135143605.html\">finance.yahoo</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-we-dont-really-know-if-a-third-covid-19-shot-is-necessary-135143605.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120326613","content_text":"Amid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.\n\"We don't really know\" if a third shot will be the final or if more are needed, Hoge told Yahoo Finance.\nIn addition, who would benefit most from an additional shot is still a question.\n\"This is the key scientific question we're all wrestling with now,\" Hoge said.\nIf an additional dose does prove to provide some level of increased protection, it would likely be necessary when late fall and winter approach, when respiratory illnesses thrive and breakthrough cases are likely to increase, he noted.\nHealth experts have been watching the upcoming seasons with dread, anticipating yet another surge in cases nationwide. The severity of those cases could be low considering the higher levels of vaccination, but the Delta variant is proving to be capable of increasing breakthrough cases and other variants could develop and spread by the year's end.\nIt's why some experts have said that the current level of vaccination is sufficient and the memory cells, whose job it is to remember how to fight off COVID-19 after being trained by the vaccine, should be relied on.\nOthers however are relying on antibody levels, which are typically highest after a vaccine, in order to determine when to boost.\nBut Hoge said he disagrees the two are mutually exclusive. \"We think ... the debate between whether it's memory cells or antibody titers is a bit false. Both are important,\" he said.\nIn data released Wednesday, Moderna showed better protection against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the elderly and immunocompromised — the latter of which has already received authorization for boosters by the FDA.\nModerna is also seeking authorization for its booster dose, which is 50 micrograms, half the dose of the original shot. It anticipates getting FDA authorization not long after Pfizer (PFE), whose advisory panel hearing is set for September 17.\nManufacturing boost for Moderna\nIn addition, Moderna is eyeing the potential to increase manufacturing as a result of a lower booster dose. That's an area where, unlike the other vaccine companies, Moderna still lags.\nThe once-small biotech has seen a boost in the company's stock since arriving on the COVID-19 vaccine scene last year. The surge in available capital is allowing it to increase its manufacturing amid the pandemic but at a slower pace.\n\"For us as a company, we are flat out in manufacturing,\" Hoge said.\nThe company has relied on third parties, known as contract manufacturers, which hasn't been without problems, which is why the company has to focus on expansion while still making good on existing dose commitments.\n\"We are making as much as we can, and have been for the better part of a year — and will be for the better part of the next year. We are trying to scale up and invest in manufacturing to create more doses,\" Hoge said.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5900405,"gmtCreate":1631859325352,"gmtModify":1631888961688,"authorId":4088412711170620,"author":{"id":4088412711170620,"idStr":"4088412711170620","authorId":4088412711170620,"name":"41e183","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884329916,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"}],"langContent":"EN"},{"id":884387157,"gmtCreate":1631857597379,"gmtModify":1631891377884,"author":{"id":"3577956622347630","authorId":"3577956622347630","name":"31ef55f0","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3577956622347630","authorIdStr":"3577956622347630"},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/884387157","repostId":1120326613,"repostType":4,"repost":{"id":"1120326613","kind":"news","pubTimestamp":1631857028,"share":"https://www.laohu8.com/m/news/1120326613?lang=zh_CN&edition=full","pubTime":"2021-09-17 13:37","market":"us","language":"en","title":"Moderna president: ‘We don't really know' if future COVID-19 shots will be necessary<blockquote>Moderna总裁：“我们真的不知道”未来是否有必要注射COVID-19疫苗</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1120326613","media":"finance.yahoo","summary":"Amid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses","content":"Amid the&nbsp;growing controversy&nbsp;over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.<blockquote>Moderna(MRNA)总裁斯蒂芬·霍格(Stephen Hoge)承认，关于美国是否需要加强疫苗或额外疫苗剂量来预防COVID-19的争议越来越大。</blockquote> \"We don't really know\" if a third shot will be the final or if more are needed, Hoge told Yahoo Finance.<blockquote>霍格告诉雅虎财经，“我们真的不知道”第三次注射是否会是最后一次，或者是否需要更多。</blockquote> In addition, who would benefit most from an additional shot is still a question.<blockquote>此外，谁将从额外的注射中受益最大仍然是一个问题。</blockquote> \"This is the key scientific question we're all wrestling with now,\" Hoge said.<blockquote>“这是我们现在都在努力解决的关键科学问题，”霍格说。</blockquote> If an additional dose does prove to provide some level of increased protection, it would likely be necessary when late fall and winter approach, when respiratory illnesses thrive and breakthrough cases are likely to increase, he noted.<blockquote>他指出，如果额外剂量确实被证明可以提供某种程度的增强保护，那么当深秋和冬季临近时，呼吸道疾病猖獗，突破性病例可能会增加，这可能是必要的。</blockquote> Health experts have been watching the upcoming seasons with dread, anticipating yet another surge in cases nationwide. The severity of those cases could be low considering the higher levels of vaccination, but the Delta variant is proving to be capable of increasing breakthrough cases and other variants could develop and spread by the year's end.<blockquote>健康专家一直在恐惧地关注着即将到来的季节，预计全国范围内的病例将再次激增。考虑到疫苗接种水平较高，这些病例的严重程度可能较低，但事实证明，德尔塔变异毒株有能力增加突破性病例，其他变种可能会在年底前发展和传播。</blockquote> It's why some experts have said that the current level of vaccination is sufficient and the memory cells, whose job it is to remember how to fight off COVID-19 after being trained by the vaccine, should be relied on.<blockquote>这就是为什么一些专家说，目前的疫苗接种水平是足够的，应该依靠记忆细胞，记忆细胞的工作是在接受疫苗训练后记住如何击退新冠肺炎。</blockquote> Others however are relying on antibody levels, which are typically highest after a vaccine, in order to determine when to boost.<blockquote>然而，其他人依靠抗体水平（通常在接种疫苗后最高）来确定何时加强免疫。</blockquote> But Hoge said he disagrees the two are mutually exclusive. \"We think ... the debate between whether it's memory cells or antibody titers is a bit false. Both are important,\" he said.<blockquote>但是霍格说他不同意这两者是相互排斥的。“我们认为……关于记忆细胞还是抗体滴度的争论有点错误。两者都很重要，”他说。</blockquote> In data released Wednesday,&nbsp;Moderna showed better protection&nbsp;against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the elderly and immunocompromised — the latter of which has already received authorization for boosters by the FDA.<blockquote>在周三发布的数据中，与一年后相比，Moderna在首次注射8个月后对突破性病例表现出更好的保护作用。但最大的好处将来自老年人和免疫功能低下者——后者已经获得了FDA的加强剂授权。</blockquote> Moderna is also seeking authorization for its booster dose, which is 50 micrograms, half the dose of the original shot. It anticipates getting FDA authorization not long after Pfizer (PFE), whose advisory panel hearing is set for September 17.<blockquote>Moderna还在寻求其加强剂量的授权，该剂量为50微克，是原始注射剂量的一半。预计辉瑞(PFE)将在辉瑞(PFE)的顾问小组听证会定于9月17日举行后不久获得FDA授权。</blockquote> Manufacturing boost for Moderna<blockquote>Moderna的制造业增长</blockquote> In addition, Moderna is eyeing the potential to&nbsp;increase manufacturing&nbsp;as a result of a lower booster dose. That's an area where, unlike the other vaccine companies, Moderna still lags.<blockquote>此外，Moderna正在关注由于较低的加强剂量而增加产量的潜力。与其他疫苗公司不同，Moderna在这一领域仍然落后。</blockquote> The once-small biotech has seen a boost in the company's stock since arriving on the COVID-19 vaccine scene last year. The surge in available capital is allowing it to increase its manufacturing amid the pandemic but at a slower pace.<blockquote>自去年进入COVID-19疫苗领域以来，这家曾经规模较小的生物技术公司的股价有所上涨。可用资本的激增使其能够在疫情期间增加制造业，但速度较慢。</blockquote> \"For us as a company, we are flat out in manufacturing,\" Hoge said.<blockquote>“对于我们作为一家公司来说，我们在制造业方面全力以赴，”霍格说。</blockquote> The company has relied on third parties, known as contract manufacturers, which&nbsp;hasn't been without problems, which is why the company has to focus on expansion while still making good on existing dose commitments.<blockquote>该公司一直依赖第三方，即合同制造商，这并非没有问题，这就是为什么该公司必须专注于扩张，同时仍然兑现现有的剂量承诺。</blockquote> \"We are making as much as we can, and have been for the better part of a year — and will be for the better part of the next year. We are trying to scale up and invest in manufacturing to create more doses,\" Hoge said.<blockquote>霍格说：“我们正在尽可能多地生产，今年的大部分时间都是如此，明年的大部分时间也将如此。我们正在努力扩大规模并投资于制造，以生产更多剂量。”</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna president: ‘We don't really know' if future COVID-19 shots will be necessary<blockquote>Moderna总裁：“我们真的不知道”未来是否有必要注射COVID-19疫苗</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna president: ‘We don't really know' if future COVID-19 shots will be necessary<blockquote>Moderna总裁：“我们真的不知道”未来是否有必要注射COVID-19疫苗</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nfinance.yahoo2021-09-17 13:37\n\n</h4>\n</header>\n<article>\nAmid the&nbsp;growing controversy&nbsp;over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.<blockquote>Moderna(MRNA)总裁斯蒂芬·霍格(Stephen Hoge)承认，关于美国是否需要加强疫苗或额外疫苗剂量来预防COVID-19的争议越来越大。</blockquote> \"We don't really know\" if a third shot will be the final or if more are needed, Hoge told Yahoo Finance.<blockquote>霍格告诉雅虎财经，“我们真的不知道”第三次注射是否会是最后一次，或者是否需要更多。</blockquote> In addition, who would benefit most from an additional shot is still a question.<blockquote>此外，谁将从额外的注射中受益最大仍然是一个问题。</blockquote> \"This is the key scientific question we're all wrestling with now,\" Hoge said.<blockquote>“这是我们现在都在努力解决的关键科学问题，”霍格说。</blockquote> If an additional dose does prove to provide some level of increased protection, it would likely be necessary when late fall and winter approach, when respiratory illnesses thrive and breakthrough cases are likely to increase, he noted.<blockquote>他指出，如果额外剂量确实被证明可以提供某种程度的增强保护，那么当深秋和冬季临近时，呼吸道疾病猖獗，突破性病例可能会增加，这可能是必要的。</blockquote> Health experts have been watching the upcoming seasons with dread, anticipating yet another surge in cases nationwide. The severity of those cases could be low considering the higher levels of vaccination, but the Delta variant is proving to be capable of increasing breakthrough cases and other variants could develop and spread by the year's end.<blockquote>健康专家一直在恐惧地关注着即将到来的季节，预计全国范围内的病例将再次激增。考虑到疫苗接种水平较高，这些病例的严重程度可能较低，但事实证明，德尔塔变异毒株有能力增加突破性病例，其他变种可能会在年底前发展和传播。</blockquote> It's why some experts have said that the current level of vaccination is sufficient and the memory cells, whose job it is to remember how to fight off COVID-19 after being trained by the vaccine, should be relied on.<blockquote>这就是为什么一些专家说，目前的疫苗接种水平是足够的，应该依靠记忆细胞，记忆细胞的工作是在接受疫苗训练后记住如何击退新冠肺炎。</blockquote> Others however are relying on antibody levels, which are typically highest after a vaccine, in order to determine when to boost.<blockquote>然而，其他人依靠抗体水平（通常在接种疫苗后最高）来确定何时加强免疫。</blockquote> But Hoge said he disagrees the two are mutually exclusive. \"We think ... the debate between whether it's memory cells or antibody titers is a bit false. Both are important,\" he said.<blockquote>但是霍格说他不同意这两者是相互排斥的。“我们认为……关于记忆细胞还是抗体滴度的争论有点错误。两者都很重要，”他说。</blockquote> In data released Wednesday,&nbsp;Moderna showed better protection&nbsp;against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the elderly and immunocompromised — the latter of which has already received authorization for boosters by the FDA.<blockquote>在周三发布的数据中，与一年后相比，Moderna在首次注射8个月后对突破性病例表现出更好的保护作用。但最大的好处将来自老年人和免疫功能低下者——后者已经获得了FDA的加强剂授权。</blockquote> Moderna is also seeking authorization for its booster dose, which is 50 micrograms, half the dose of the original shot. It anticipates getting FDA authorization not long after Pfizer (PFE), whose advisory panel hearing is set for September 17.<blockquote>Moderna还在寻求其加强剂量的授权，该剂量为50微克，是原始注射剂量的一半。预计辉瑞(PFE)将在辉瑞(PFE)的顾问小组听证会定于9月17日举行后不久获得FDA授权。</blockquote> Manufacturing boost for Moderna<blockquote>Moderna的制造业增长</blockquote> In addition, Moderna is eyeing the potential to&nbsp;increase manufacturing&nbsp;as a result of a lower booster dose. That's an area where, unlike the other vaccine companies, Moderna still lags.<blockquote>此外，Moderna正在关注由于较低的加强剂量而增加产量的潜力。与其他疫苗公司不同，Moderna在这一领域仍然落后。</blockquote> The once-small biotech has seen a boost in the company's stock since arriving on the COVID-19 vaccine scene last year. The surge in available capital is allowing it to increase its manufacturing amid the pandemic but at a slower pace.<blockquote>自去年进入COVID-19疫苗领域以来，这家曾经规模较小的生物技术公司的股价有所上涨。可用资本的激增使其能够在疫情期间增加制造业，但速度较慢。</blockquote> \"For us as a company, we are flat out in manufacturing,\" Hoge said.<blockquote>“对于我们作为一家公司来说，我们在制造业方面全力以赴，”霍格说。</blockquote> The company has relied on third parties, known as contract manufacturers, which&nbsp;hasn't been without problems, which is why the company has to focus on expansion while still making good on existing dose commitments.<blockquote>该公司一直依赖第三方，即合同制造商，这并非没有问题，这就是为什么该公司必须专注于扩张，同时仍然兑现现有的剂量承诺。</blockquote> \"We are making as much as we can, and have been for the better part of a year — and will be for the better part of the next year. We are trying to scale up and invest in manufacturing to create more doses,\" Hoge said.<blockquote>霍格说：“我们正在尽可能多地生产，今年的大部分时间都是如此，明年的大部分时间也将如此。我们正在努力扩大规模并投资于制造，以生产更多剂量。”</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-we-dont-really-know-if-a-third-covid-19-shot-is-necessary-135143605.html\">finance.yahoo</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-we-dont-really-know-if-a-third-covid-19-shot-is-necessary-135143605.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120326613","content_text":"Amid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.\n\"We don't really know\" if a third shot will be the final or if more are needed, Hoge told Yahoo Finance.\nIn addition, who would benefit most from an additional shot is still a question.\n\"This is the key scientific question we're all wrestling with now,\" Hoge said.\nIf an additional dose does prove to provide some level of increased protection, it would likely be necessary when late fall and winter approach, when respiratory illnesses thrive and breakthrough cases are likely to increase, he noted.\nHealth experts have been watching the upcoming seasons with dread, anticipating yet another surge in cases nationwide. The severity of those cases could be low considering the higher levels of vaccination, but the Delta variant is proving to be capable of increasing breakthrough cases and other variants could develop and spread by the year's end.\nIt's why some experts have said that the current level of vaccination is sufficient and the memory cells, whose job it is to remember how to fight off COVID-19 after being trained by the vaccine, should be relied on.\nOthers however are relying on antibody levels, which are typically highest after a vaccine, in order to determine when to boost.\nBut Hoge said he disagrees the two are mutually exclusive. \"We think ... the debate between whether it's memory cells or antibody titers is a bit false. Both are important,\" he said.\nIn data released Wednesday, Moderna showed better protection against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the elderly and immunocompromised — the latter of which has already received authorization for boosters by the FDA.\nModerna is also seeking authorization for its booster dose, which is 50 micrograms, half the dose of the original shot. It anticipates getting FDA authorization not long after Pfizer (PFE), whose advisory panel hearing is set for September 17.\nManufacturing boost for Moderna\nIn addition, Moderna is eyeing the potential to increase manufacturing as a result of a lower booster dose. That's an area where, unlike the other vaccine companies, Moderna still lags.\nThe once-small biotech has seen a boost in the company's stock since arriving on the COVID-19 vaccine scene last year. The surge in available capital is allowing it to increase its manufacturing amid the pandemic but at a slower pace.\n\"For us as a company, we are flat out in manufacturing,\" Hoge said.\nThe company has relied on third parties, known as contract manufacturers, which hasn't been without problems, which is why the company has to focus on expansion while still making good on existing dose commitments.\n\"We are making as much as we can, and have been for the better part of a year — and will be for the better part of the next year. We are trying to scale up and invest in manufacturing to create more doses,\" Hoge said.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5901974,"gmtCreate":1631871223533,"gmtModify":1631891377929,"authorId":3580988274582448,"author":{"id":3580988274582448,"idStr":"3580988274582448","authorId":3580988274582448,"name":"DragonKing","avatar":"https://static.tigerbbs.com/999074a932b6e7b44c07fcebc581aacb","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3576232257279797,"repliedAuthor":{"id":3576232257279797,"idStr":"3576232257279797","authorId":3576232257279797,"name":"43c0b98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":884387157,"type":1,"supId":5900296,"prevId":5900298,"content":"yeah","text":"yeah","html":"yeah"},{"id":5900680,"gmtCreate":1631861746655,"gmtModify":1631891377918,"authorId":3585997214465926,"author":{"id":3585997214465926,"idStr":"3585997214465926","authorId":3585997214465926,"name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884387157,"type":1,"supId":0,"prevId":0,"content":"h","text":"h","html":"h"},{"id":5900350,"gmtCreate":1631858650481,"gmtModify":1631891377904,"authorId":3577097645660752,"author":{"id":3577097645660752,"idStr":"3577097645660752","authorId":3577097645660752,"name":"JiaLe","avatar":"https://static.tigerbbs.com/24a1ed581cfd6c2dbde8ebd02058830d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884387157,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5900298,"gmtCreate":1631858139270,"gmtModify":1631891377893,"authorId":3576232257279797,"author":{"id":3576232257279797,"idStr":"3576232257279797","authorId":3576232257279797,"name":"43c0b98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884387157,"type":1,"supId":5900296,"prevId":0,"content":"Time to piak piak already la","text":"Time to piak piak already la","html":"Time to piak piak already la"},{"id":5900296,"gmtCreate":1631858109926,"gmtModify":1631891377882,"authorId":3580988274582448,"author":{"id":3580988274582448,"idStr":"3580988274582448","authorId":3580988274582448,"name":"DragonKing","avatar":"https://static.tigerbbs.com/999074a932b6e7b44c07fcebc581aacb","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884387157,"type":1,"supId":0,"prevId":0,"content":"done. like pls.","text":"done. like pls.","html":"done. like pls."}],"langContent":"EN"},{"id":884386751,"gmtCreate":1631857140973,"gmtModify":1632805745992,"author":{"id":"4094813786298510","authorId":"4094813786298510","name":"Catherinee","avatar":"https://static.tigerbbs.com/e8ed058354759441f902154fde4b0eed","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"4094813786298510","authorIdStr":"4094813786298510"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/884386751","repostId":1120326613,"repostType":4,"repost":{"id":"1120326613","kind":"news","pubTimestamp":1631857028,"share":"https://www.laohu8.com/m/news/1120326613?lang=zh_CN&edition=full","pubTime":"2021-09-17 13:37","market":"us","language":"en","title":"Moderna president: ‘We don't really know' if future COVID-19 shots will be necessary<blockquote>Moderna总裁：“我们真的不知道”未来是否有必要注射COVID-19疫苗</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1120326613","media":"finance.yahoo","summary":"Amid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses","content":"Amid the&nbsp;growing controversy&nbsp;over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.<blockquote>Moderna(MRNA)总裁斯蒂芬·霍格(Stephen Hoge)承认，关于美国是否需要加强疫苗或额外疫苗剂量来预防COVID-19的争议越来越大。</blockquote> \"We don't really know\" if a third shot will be the final or if more are needed, Hoge told Yahoo Finance.<blockquote>霍格告诉雅虎财经，“我们真的不知道”第三次注射是否会是最后一次，或者是否需要更多。</blockquote> In addition, who would benefit most from an additional shot is still a question.<blockquote>此外，谁将从额外的注射中受益最大仍然是一个问题。</blockquote> \"This is the key scientific question we're all wrestling with now,\" Hoge said.<blockquote>“这是我们现在都在努力解决的关键科学问题，”霍格说。</blockquote> If an additional dose does prove to provide some level of increased protection, it would likely be necessary when late fall and winter approach, when respiratory illnesses thrive and breakthrough cases are likely to increase, he noted.<blockquote>他指出，如果额外剂量确实被证明可以提供某种程度的增强保护，那么当深秋和冬季临近时，呼吸道疾病猖獗，突破性病例可能会增加，这可能是必要的。</blockquote> Health experts have been watching the upcoming seasons with dread, anticipating yet another surge in cases nationwide. The severity of those cases could be low considering the higher levels of vaccination, but the Delta variant is proving to be capable of increasing breakthrough cases and other variants could develop and spread by the year's end.<blockquote>健康专家一直在恐惧地关注着即将到来的季节，预计全国范围内的病例将再次激增。考虑到疫苗接种水平较高，这些病例的严重程度可能较低，但事实证明，德尔塔变异毒株有能力增加突破性病例，其他变种可能会在年底前发展和传播。</blockquote> It's why some experts have said that the current level of vaccination is sufficient and the memory cells, whose job it is to remember how to fight off COVID-19 after being trained by the vaccine, should be relied on.<blockquote>这就是为什么一些专家说，目前的疫苗接种水平是足够的，应该依靠记忆细胞，记忆细胞的工作是在接受疫苗训练后记住如何击退新冠肺炎。</blockquote> Others however are relying on antibody levels, which are typically highest after a vaccine, in order to determine when to boost.<blockquote>然而，其他人依靠抗体水平（通常在接种疫苗后最高）来确定何时加强免疫。</blockquote> But Hoge said he disagrees the two are mutually exclusive. \"We think ... the debate between whether it's memory cells or antibody titers is a bit false. Both are important,\" he said.<blockquote>但是霍格说他不同意这两者是相互排斥的。“我们认为……关于记忆细胞还是抗体滴度的争论有点错误。两者都很重要，”他说。</blockquote> In data released Wednesday,&nbsp;Moderna showed better protection&nbsp;against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the elderly and immunocompromised — the latter of which has already received authorization for boosters by the FDA.<blockquote>在周三发布的数据中，与一年后相比，Moderna在首次注射8个月后对突破性病例表现出更好的保护作用。但最大的好处将来自老年人和免疫功能低下者——后者已经获得了FDA的加强剂授权。</blockquote> Moderna is also seeking authorization for its booster dose, which is 50 micrograms, half the dose of the original shot. It anticipates getting FDA authorization not long after Pfizer (PFE), whose advisory panel hearing is set for September 17.<blockquote>Moderna还在寻求其加强剂量的授权，该剂量为50微克，是原始注射剂量的一半。预计辉瑞(PFE)将在辉瑞(PFE)的顾问小组听证会定于9月17日举行后不久获得FDA授权。</blockquote> Manufacturing boost for Moderna<blockquote>Moderna的制造业增长</blockquote> In addition, Moderna is eyeing the potential to&nbsp;increase manufacturing&nbsp;as a result of a lower booster dose. That's an area where, unlike the other vaccine companies, Moderna still lags.<blockquote>此外，Moderna正在关注由于较低的加强剂量而增加产量的潜力。与其他疫苗公司不同，Moderna在这一领域仍然落后。</blockquote> The once-small biotech has seen a boost in the company's stock since arriving on the COVID-19 vaccine scene last year. The surge in available capital is allowing it to increase its manufacturing amid the pandemic but at a slower pace.<blockquote>自去年进入COVID-19疫苗领域以来，这家曾经规模较小的生物技术公司的股价有所上涨。可用资本的激增使其能够在疫情期间增加制造业，但速度较慢。</blockquote> \"For us as a company, we are flat out in manufacturing,\" Hoge said.<blockquote>“对于我们作为一家公司来说，我们在制造业方面全力以赴，”霍格说。</blockquote> The company has relied on third parties, known as contract manufacturers, which&nbsp;hasn't been without problems, which is why the company has to focus on expansion while still making good on existing dose commitments.<blockquote>该公司一直依赖第三方，即合同制造商，这并非没有问题，这就是为什么该公司必须专注于扩张，同时仍然兑现现有的剂量承诺。</blockquote> \"We are making as much as we can, and have been for the better part of a year — and will be for the better part of the next year. We are trying to scale up and invest in manufacturing to create more doses,\" Hoge said.<blockquote>霍格说：“我们正在尽可能多地生产，今年的大部分时间都是如此，明年的大部分时间也将如此。我们正在努力扩大规模并投资于制造，以生产更多剂量。”</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna president: ‘We don't really know' if future COVID-19 shots will be necessary<blockquote>Moderna总裁：“我们真的不知道”未来是否有必要注射COVID-19疫苗</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna president: ‘We don't really know' if future COVID-19 shots will be necessary<blockquote>Moderna总裁：“我们真的不知道”未来是否有必要注射COVID-19疫苗</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nfinance.yahoo2021-09-17 13:37\n\n</h4>\n</header>\n<article>\nAmid the&nbsp;growing controversy&nbsp;over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.<blockquote>Moderna(MRNA)总裁斯蒂芬·霍格(Stephen Hoge)承认，关于美国是否需要加强疫苗或额外疫苗剂量来预防COVID-19的争议越来越大。</blockquote> \"We don't really know\" if a third shot will be the final or if more are needed, Hoge told Yahoo Finance.<blockquote>霍格告诉雅虎财经，“我们真的不知道”第三次注射是否会是最后一次，或者是否需要更多。</blockquote> In addition, who would benefit most from an additional shot is still a question.<blockquote>此外，谁将从额外的注射中受益最大仍然是一个问题。</blockquote> \"This is the key scientific question we're all wrestling with now,\" Hoge said.<blockquote>“这是我们现在都在努力解决的关键科学问题，”霍格说。</blockquote> If an additional dose does prove to provide some level of increased protection, it would likely be necessary when late fall and winter approach, when respiratory illnesses thrive and breakthrough cases are likely to increase, he noted.<blockquote>他指出，如果额外剂量确实被证明可以提供某种程度的增强保护，那么当深秋和冬季临近时，呼吸道疾病猖獗，突破性病例可能会增加，这可能是必要的。</blockquote> Health experts have been watching the upcoming seasons with dread, anticipating yet another surge in cases nationwide. The severity of those cases could be low considering the higher levels of vaccination, but the Delta variant is proving to be capable of increasing breakthrough cases and other variants could develop and spread by the year's end.<blockquote>健康专家一直在恐惧地关注着即将到来的季节，预计全国范围内的病例将再次激增。考虑到疫苗接种水平较高，这些病例的严重程度可能较低，但事实证明，德尔塔变异毒株有能力增加突破性病例，其他变种可能会在年底前发展和传播。</blockquote> It's why some experts have said that the current level of vaccination is sufficient and the memory cells, whose job it is to remember how to fight off COVID-19 after being trained by the vaccine, should be relied on.<blockquote>这就是为什么一些专家说，目前的疫苗接种水平是足够的，应该依靠记忆细胞，记忆细胞的工作是在接受疫苗训练后记住如何击退新冠肺炎。</blockquote> Others however are relying on antibody levels, which are typically highest after a vaccine, in order to determine when to boost.<blockquote>然而，其他人依靠抗体水平（通常在接种疫苗后最高）来确定何时加强免疫。</blockquote> But Hoge said he disagrees the two are mutually exclusive. \"We think ... the debate between whether it's memory cells or antibody titers is a bit false. Both are important,\" he said.<blockquote>但是霍格说他不同意这两者是相互排斥的。“我们认为……关于记忆细胞还是抗体滴度的争论有点错误。两者都很重要，”他说。</blockquote> In data released Wednesday,&nbsp;Moderna showed better protection&nbsp;against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the elderly and immunocompromised — the latter of which has already received authorization for boosters by the FDA.<blockquote>在周三发布的数据中，与一年后相比，Moderna在首次注射8个月后对突破性病例表现出更好的保护作用。但最大的好处将来自老年人和免疫功能低下者——后者已经获得了FDA的加强剂授权。</blockquote> Moderna is also seeking authorization for its booster dose, which is 50 micrograms, half the dose of the original shot. It anticipates getting FDA authorization not long after Pfizer (PFE), whose advisory panel hearing is set for September 17.<blockquote>Moderna还在寻求其加强剂量的授权，该剂量为50微克，是原始注射剂量的一半。预计辉瑞(PFE)将在辉瑞(PFE)的顾问小组听证会定于9月17日举行后不久获得FDA授权。</blockquote> Manufacturing boost for Moderna<blockquote>Moderna的制造业增长</blockquote> In addition, Moderna is eyeing the potential to&nbsp;increase manufacturing&nbsp;as a result of a lower booster dose. That's an area where, unlike the other vaccine companies, Moderna still lags.<blockquote>此外，Moderna正在关注由于较低的加强剂量而增加产量的潜力。与其他疫苗公司不同，Moderna在这一领域仍然落后。</blockquote> The once-small biotech has seen a boost in the company's stock since arriving on the COVID-19 vaccine scene last year. The surge in available capital is allowing it to increase its manufacturing amid the pandemic but at a slower pace.<blockquote>自去年进入COVID-19疫苗领域以来，这家曾经规模较小的生物技术公司的股价有所上涨。可用资本的激增使其能够在疫情期间增加制造业，但速度较慢。</blockquote> \"For us as a company, we are flat out in manufacturing,\" Hoge said.<blockquote>“对于我们作为一家公司来说，我们在制造业方面全力以赴，”霍格说。</blockquote> The company has relied on third parties, known as contract manufacturers, which&nbsp;hasn't been without problems, which is why the company has to focus on expansion while still making good on existing dose commitments.<blockquote>该公司一直依赖第三方，即合同制造商，这并非没有问题，这就是为什么该公司必须专注于扩张，同时仍然兑现现有的剂量承诺。</blockquote> \"We are making as much as we can, and have been for the better part of a year — and will be for the better part of the next year. We are trying to scale up and invest in manufacturing to create more doses,\" Hoge said.<blockquote>霍格说：“我们正在尽可能多地生产，今年的大部分时间都是如此，明年的大部分时间也将如此。我们正在努力扩大规模并投资于制造，以生产更多剂量。”</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-we-dont-really-know-if-a-third-covid-19-shot-is-necessary-135143605.html\">finance.yahoo</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-we-dont-really-know-if-a-third-covid-19-shot-is-necessary-135143605.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120326613","content_text":"Amid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown.\n\"We don't really know\" if a third shot will be the final or if more are needed, Hoge told Yahoo Finance.\nIn addition, who would benefit most from an additional shot is still a question.\n\"This is the key scientific question we're all wrestling with now,\" Hoge said.\nIf an additional dose does prove to provide some level of increased protection, it would likely be necessary when late fall and winter approach, when respiratory illnesses thrive and breakthrough cases are likely to increase, he noted.\nHealth experts have been watching the upcoming seasons with dread, anticipating yet another surge in cases nationwide. The severity of those cases could be low considering the higher levels of vaccination, but the Delta variant is proving to be capable of increasing breakthrough cases and other variants could develop and spread by the year's end.\nIt's why some experts have said that the current level of vaccination is sufficient and the memory cells, whose job it is to remember how to fight off COVID-19 after being trained by the vaccine, should be relied on.\nOthers however are relying on antibody levels, which are typically highest after a vaccine, in order to determine when to boost.\nBut Hoge said he disagrees the two are mutually exclusive. \"We think ... the debate between whether it's memory cells or antibody titers is a bit false. Both are important,\" he said.\nIn data released Wednesday, Moderna showed better protection against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the elderly and immunocompromised — the latter of which has already received authorization for boosters by the FDA.\nModerna is also seeking authorization for its booster dose, which is 50 micrograms, half the dose of the original shot. It anticipates getting FDA authorization not long after Pfizer (PFE), whose advisory panel hearing is set for September 17.\nManufacturing boost for Moderna\nIn addition, Moderna is eyeing the potential to increase manufacturing as a result of a lower booster dose. That's an area where, unlike the other vaccine companies, Moderna still lags.\nThe once-small biotech has seen a boost in the company's stock since arriving on the COVID-19 vaccine scene last year. The surge in available capital is allowing it to increase its manufacturing amid the pandemic but at a slower pace.\n\"For us as a company, we are flat out in manufacturing,\" Hoge said.\nThe company has relied on third parties, known as contract manufacturers, which hasn't been without problems, which is why the company has to focus on expansion while still making good on existing dose commitments.\n\"We are making as much as we can, and have been for the better part of a year — and will be for the better part of the next year. We are trying to scale up and invest in manufacturing to create more doses,\" Hoge said.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5900221,"gmtCreate":1631857343658,"gmtModify":1634796789584,"authorId":3573986430688942,"author":{"id":3573986430688942,"idStr":"3573986430688942","authorId":3573986430688942,"name":"themonkey","avatar":"https://static.tigerbbs.com/573a67d390101884216129f5c49fe8a0","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884386751,"type":1,"supId":0,"prevId":0,"content":"yes","text":"yes","html":"yes"},{"id":5900254,"gmtCreate":1631857603843,"gmtModify":1634796786545,"authorId":3577956622347630,"author":{"id":3577956622347630,"idStr":"3577956622347630","authorId":3577956622347630,"name":"31ef55f0","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884386751,"type":1,"supId":0,"prevId":0,"content":"Yes ","text":"Yes ","html":"Yes "},{"id":5900302,"gmtCreate":1631858148638,"gmtModify":1634796782127,"authorId":3576232257279797,"author":{"id":3576232257279797,"idStr":"3576232257279797","authorId":3576232257279797,"name":"43c0b98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884386751,"type":1,"supId":0,"prevId":0,"content":"Time to piak piak already la","text":"Time to piak piak already la","html":"Time to piak piak already la"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":41,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}